Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.53 |
| ▸ | PGR | P06401 | 4/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 3/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3650311 | 0.85 | NR3C1 (0.71) | NR3C1PGRNR3C2 | |
| SCHEMBL5777800 | 0.84 | NR3C1 (0.67) | NR3C1PGRNR3C2CYP3A4USP1 | |
| SCHEMBL3535960 | 0.84 | NR3C1 (0.55) | NR3C1PGRNR3C2USP1WDR48 | |
| SCHEMBL6408293 | 0.84 | NR3C1 (0.77) | NR3C1PGRNR3C2CYP3A4 | |
| SCHEMBL3649830 | 0.83 | NR3C1 (0.69) | NR3C1PGRNR3C2 | |
| SCHEMBL5798055 | 0.83 | NR3C1 (0.56) | NR3C1PGRNR3C2USP1WDR48 | |
| SCHEMBL6405034 | 0.81 | NR3C1 (0.78) | NR3C1PGRNR3C2 | |
| SCHEMBL6402666 | 0.81 | NR3C1 (0.57) | NR3C1PGRNR3C2USP1WDR48 | |
| SCHEMBL4817558 | 0.78 | NR3C1 (0.66) | NR3C1PGRNR3C2USP1WDR48 | |
| SCHEMBL6406127 | 0.76 | NR3C1 (0.40) | NR3C1PGRNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | NR3C1 1483/4885PGR 3289/4885NR3C2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.